|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C16orf74 |
Gene summary for C16ORF74 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C16orf74 | Gene ID | 404550 |
| Gene name | chromosome 16 open reading frame 74 | |
| Gene Alias | C16orf74 | |
| Cytomap | 16q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | A0A0M5MPK6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 404550 | C16orf74 | LZE2T | Human | Esophagus | ESCC | 2.56e-09 | 1.37e+00 | 0.082 |
| 404550 | C16orf74 | LZE4T | Human | Esophagus | ESCC | 1.24e-02 | 1.25e-01 | 0.0811 |
| 404550 | C16orf74 | LZE20T | Human | Esophagus | ESCC | 8.46e-16 | 6.01e-01 | 0.0662 |
| 404550 | C16orf74 | LZE21D1 | Human | Esophagus | HGIN | 2.84e-02 | 4.09e-01 | 0.0632 |
| 404550 | C16orf74 | LZE22D1 | Human | Esophagus | HGIN | 2.42e-04 | 3.10e-01 | 0.0595 |
| 404550 | C16orf74 | LZE22T | Human | Esophagus | ESCC | 1.46e-18 | 1.18e+00 | 0.068 |
| 404550 | C16orf74 | LZE24T | Human | Esophagus | ESCC | 1.15e-21 | 6.58e-01 | 0.0596 |
| 404550 | C16orf74 | LZE21T | Human | Esophagus | ESCC | 6.48e-13 | 8.22e-01 | 0.0655 |
| 404550 | C16orf74 | P1T-E | Human | Esophagus | ESCC | 1.04e-21 | 9.16e-01 | 0.0875 |
| 404550 | C16orf74 | P2T-E | Human | Esophagus | ESCC | 2.72e-16 | 3.67e-01 | 0.1177 |
| 404550 | C16orf74 | P4T-E | Human | Esophagus | ESCC | 4.53e-41 | 1.02e+00 | 0.1323 |
| 404550 | C16orf74 | P5T-E | Human | Esophagus | ESCC | 1.19e-37 | 8.29e-01 | 0.1327 |
| 404550 | C16orf74 | P8T-E | Human | Esophagus | ESCC | 1.78e-11 | 3.04e-01 | 0.0889 |
| 404550 | C16orf74 | P9T-E | Human | Esophagus | ESCC | 3.29e-32 | 8.09e-01 | 0.1131 |
| 404550 | C16orf74 | P10T-E | Human | Esophagus | ESCC | 5.70e-86 | 1.66e+00 | 0.116 |
| 404550 | C16orf74 | P11T-E | Human | Esophagus | ESCC | 3.22e-22 | 8.86e-01 | 0.1426 |
| 404550 | C16orf74 | P12T-E | Human | Esophagus | ESCC | 3.72e-41 | 7.62e-01 | 0.1122 |
| 404550 | C16orf74 | P15T-E | Human | Esophagus | ESCC | 8.36e-57 | 1.30e+00 | 0.1149 |
| 404550 | C16orf74 | P16T-E | Human | Esophagus | ESCC | 3.50e-31 | 5.60e-01 | 0.1153 |
| 404550 | C16orf74 | P17T-E | Human | Esophagus | ESCC | 2.71e-13 | 7.09e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C16orf74 | SNV | Missense_Mutation | c.70G>A | p.Glu24Lys | p.E24K | Q96GX8 | protein_coding | tolerated_low_confidence(0.08) | possibly_damaging(0.759) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| C16orf74 | SNV | Missense_Mutation | rs374680936 | c.122C>T | p.Thr41Met | p.T41M | Q96GX8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-A6-A56B-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | fluorouracil | PD |
| C16orf74 | SNV | Missense_Mutation | novel | c.172G>T | p.Val58Phe | p.V58F | Q96GX8 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.555) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |